Roche Diagnostics has launched its new molecular laboratory instrument, the cobas® 5800 System, within the UK. By improved automation the brand new system may help elevate testing volumes, enhance operational effectivity and handle the growing demand that many laboratories are experiencing.
The system has a small footprint making it accessible to many extra laboratories, notably these with much less house. The absolutely automated system, which consolidates 90% of routine testing on a single platform, minimizes laboratory employees’ hands-on time and improves productiveness. The system offers a scalable answer for smaller labs searching for huge lab efficiency, or for greater labs searching for small lab agility.
The cobas® 5800 will likely be out there for demos on the Institute of Biomedical Science (IBMS) Congress on 14-17 March 2022.
The processing digital platform it makes use of, the Molecular Work Space, at present performs over 10 million assessments monthly on greater than 1,000 put in programs world wide.
Geoff Twist, Managing Director of Roche Diagnostics UK and Eire stated:
“Clinicians and sufferers depend on correct and well timed outcomes to make knowledgeable choices, and in vitro testing on programs just like the cobas® 5800 play an important position in serving to the NHS to offer these leads to a extremely pressurized setting.
“The NHS is going through one other exceptionally difficult interval – because it continues to answer COVID-19 while additionally tackling the large backlog of sufferers which has constructed up through the pandemic – and we’re delighted to convey the compact cobas® 5800 to the UK market at a time when labs up and down the nation are working tougher than ever.”
The necessity for versatile, dependable, fully-automated diagnostic options has by no means been extra acute. By constructing on a system with confirmed reliability and efficiency, we proceed to simplify laboratory operations to assist guarantee sufferers are recognized and placed on the fitting remedy pathway as shortly as attainable.”
Geoff Twist, Managing Director of Roche Diagnostics UK and Eire
#Roche #Diagnostics #introduces #molecular #laboratory #instrument